These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 36260194)

  • 21. Immucillins Impair Leishmania (L.) infantum chagasi and Leishmania (L.) amazonensis Multiplication In Vitro.
    Freitas EO; Nico D; Guan R; Meyer-Fernandes JR; Clinch K; Evans GB; Tyler PC; Schramm VL; Palatnik-de-Sousa CB
    PLoS One; 2015; 10(4):e0124183. PubMed ID: 25909893
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum.
    Gómez Pérez V; García-Hernandez R; Corpas-López V; Tomás AM; Martín-Sanchez J; Castanys S; Gamarro F
    Int J Parasitol Drugs Drug Resist; 2016 Aug; 6(2):133-9. PubMed ID: 27317865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro and in vivo antileishmanial activity of a fluoroquinoline derivate against Leishmania infantum and Leishmania amazonensis species.
    Tavares GSV; Mendonça DVC; Lage DP; Antinarelli LMR; Soyer TG; Senna AJS; Matos GF; Dias DS; Ribeiro PAF; Batista JPT; Poletto JM; Brandão GC; Chávez-Fumagalli MA; Pereira GR; Coimbra ES; Coelho EAF
    Acta Trop; 2019 Mar; 191():29-37. PubMed ID: 30586571
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Host resistance to visceral leishmaniasis: prevalence and prevention.
    Maran N; Gomes PS; Freire-de-Lima L; Freitas EO; Freire-de-Lima CG; Morrot A
    Expert Rev Anti Infect Ther; 2016; 14(4):435-42. PubMed ID: 26934623
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro.
    Allahverdiyev AM; Abamor ES; Bagirova M; Baydar SY; Ates SC; Kaya F; Kaya C; Rafailovich M
    Exp Parasitol; 2013 Sep; 135(1):55-63. PubMed ID: 23792003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain.
    Rai K; Cuypers B; Bhattarai NR; Uranw S; Berg M; Ostyn B; Dujardin JC; Rijal S; Vanaerschot M
    mBio; 2013 Oct; 4(5):e00611-13. PubMed ID: 24105765
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parasitological and immunological evaluation of a quinoline derivative salt incorporated into a polymeric micelle formulation against Leishmania infantum infection.
    Ribeiro Antinarelli LM; Glanzmann N; Mendonça DVC; Lage DP; Oliveira-da-Silva JA; Tavares GSV; Carvalho AMRS; Freitas CS; Martins VT; Duarte MC; Menezes-Souza D; da Silva AD; Coelho EAF; Soares Coimbra E
    Parasitol Res; 2022 Jul; 121(7):2129-2140. PubMed ID: 35614147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Parasitological and immunological evaluation of a novel chemotherapeutic agent against visceral leishmaniasis.
    Pereira IAG; Mendonça DVC; Tavares GSV; Lage DP; Ramos FF; Oliveira-da-Silva JA; Antinarelli LMR; Machado AS; Carvalho LM; Carvalho AMRS; Salustiano IV; Reis TAR; Bandeira RS; Silva AM; Martins VT; Chávez-Fumagalli MA; Humbert MV; Roatt BM; Duarte MC; Menezes-Souza D; Coimbra ES; Leite JPV; Coelho EAF; Gonçalves DU
    Parasite Immunol; 2020 Dec; 42(12):e12784. PubMed ID: 32772379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Leishmania donovani Impedes Antileishmanial Immunity by Suppressing Dendritic Cells via the TIM-3 Receptor.
    Akhtar MN; Kumar S; Sen P
    mBio; 2022 Aug; 13(4):e0330921. PubMed ID: 35924848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nano- and Microformulations to Advance Therapies for Visceral Leishmaniasis.
    Varma DM; Redding EA; Bachelder EM; Ainslie KM
    ACS Biomater Sci Eng; 2021 May; 7(5):1725-1741. PubMed ID: 33966377
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pamidronate, a promising repositioning drug to treat leishmaniasis, displays antileishmanial and immunomodulatory potential.
    Ribeiro JM; Rodrigues-Alves ML; Oliveira E; Guimarães PPG; Maria Murta Santi A; Teixeira-Carvalho A; Murta SMF; Peruhype-Magalhães V; Souza-Fagundes EM
    Int Immunopharmacol; 2022 Sep; 110():108952. PubMed ID: 35716482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic Potential of Quercetin-Loaded Nanoemulsion against Experimental Visceral Leishmaniasis:
    Das SS; Dubey AK; Verma PRP; Singh SK; Singh SK
    Mol Pharm; 2022 Sep; 19(9):3367-3384. PubMed ID: 35980291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity and Cell-Death Pathway in
    Scariot DB; Volpato H; Fernandes NS; Soares EFP; Ueda-Nakamura T; Dias-Filho BP; Din ZU; Rodrigues-Filho E; Rubira AF; Borges O; Sousa MDC; Nakamura CV
    Front Cell Infect Microbiol; 2019; 9():208. PubMed ID: 31259161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the repositioning of the amodiaquine as potential drug against visceral leishmaniasis: The in vitro effect against Leishmania infantum is associated with multiple mechanisms, involving mitochondria dysfunction, oxidative stress and loss of cell cycle control.
    Antinarelli LMR; Midlej V; da Silva EDS; Coelho EAF; da Silva AD; Coimbra ES
    Chem Biol Interact; 2023 Feb; 371():110333. PubMed ID: 36592711
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
    Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
    PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening of Novel Inhibitors Against Leishmania donovani Calcium ion Channel to Fight Leishmaniasis.
    Kashif M; Manna PP; Akhter Y; Alaidarous M; Rub A
    Infect Disord Drug Targets; 2017; 17(2):120-129. PubMed ID: 28034363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Histamine H1-receptor antagonists against Leishmania (L.) infantum: an in vitro and in vivo evaluation using phosphatidylserine-liposomes.
    Pinto EG; da Costa-Silva TA; Tempone AG
    Acta Trop; 2014 Sep; 137():206-10. PubMed ID: 24905294
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flau-A, a naphthoquinone derivative, is a promising therapeutic candidate against visceral leishmaniasis: A preliminary study.
    Mendonça DVC; Tavares GSV; Pereira IAG; Oliveira-da-Silva JA; Ramos FF; Lage DP; Machado AS; Carvalho LM; Reis TAR; Carvalho AMRS; Ottoni FM; Ludolf F; Freitas CS; Martins VT; Chávez-Fumagalli MA; Duarte MC; Humbert MV; Roatt BM; Menezes-Souza D; Alves RJ; Coelho EAF
    Exp Parasitol; 2022 Feb; 233():108205. PubMed ID: 34968460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Apigenin is a promising molecule for treatment of visceral leishmaniasis.
    Emiliano YSS; Almeida-Amaral EE
    Front Cell Infect Microbiol; 2023; 13():1066407. PubMed ID: 37091674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model.
    da Costa-Silva TA; Galisteo AJ; Lindoso JA; Barbosa LR; Tempone AG
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167544
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.